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The first review on biomaterials for the treatment of myocardial infarction (MI) was written in 2006. In the last
5 years, the general approaches for biomaterial treatment of MI and subsequent left ventricular remodeling re-
main the same, namely, left ventricular restraints, epicardial patches, and injectable therapies. Nonetheless,
there have been significant developments in this field, including advancement of biomaterial therapies to large
animal pre-clinical studies and, more recently, to clinical trials. This review focuses on the progress made in the
field of cardiac biomaterial treatments for MI over the last 5 years. (J Am Coll Cardiol 2011;58:2615–29)
© 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.001With myocardial infarction (MI) as a major contributor to
cardiovascular disease, the leading cause of death in the
Western world, there is a rising need for novel therapies for
treatment of post-MI negative left ventricular (LV) remod-
eling. Although LV remodeling post-MI can be beneficial
at first, over time, this compensatory mechanism can be
maladaptive, ultimately leading to heart failure (1). Cur-
rently, pharmacologics, total heart transplantation, and LV
assist devices are the only widespread forms of remedy.
Cellular transplantation has been explored for almost 2
decades now, with numerous ongoing clinical trials; how-
ever, significant gains in cardiac function have yet to be
realized. Nonetheless, over the last decade or so, biomaterial
technologies have emerged and have shown great promise as
potential treatments for MI.
Biomaterials for the treatment of MI were first reviewed
5 years ago (2). Over the last 5 years, the general biomaterial
approaches to treatment of MI have remained the same: LV
restraints, cardiac patches, and injectable approaches (Fig. 1).
Although the numbers are small, we are now beginning to
see clinical trials with cardiac patches and, most recently,
injectable biomaterials, demonstrating that the biomaterial
approach to MI treatment is moving forward at a rapid pace.
This review focuses on the advancements made over the last
5 years in the use of biomaterials for the treatment of MI
(Tables 1 and 2). Only biomaterials that have been utilized
for the treatment of MI in vivo are discussed.
From the Department of Bioengineering, University of California-San Diego, La
Jolla, California. Ms. Rane has reported that she has no relationships relevant to the
contents of this paper to disclose. Dr. Christman is the cofounder of Ventrix Inc.
D. Geoffrey Vince, PhD, served as the Guest Editor for this paper.Manuscript received August 16, 2011; revised manuscript received October 28,
2011, accepted November 1, 2011.LV Restraints
Previously, numerous studies evaluated the use of biomate-
rial supports to constrain the LV. In the last 5 years, one
advancement is Paracor’s HeartNet LV support system—a
nitinol mesh weave (Paracor Medical, Sunnyvale, Califor-
nia) that is placed around the ventricles—which has been
shown to reduce LV end-diastolic (ED) and end-systolic
(ES) volume indices and LV mass in an ovine MI model (3),
and reduce ED volume and increase mean arterial pressure
and LV pressures in a canine chronic heart failure model (4).
Paracor has undergone an initial clinical feasibility study (5),
and is in their pivotal trial titled the PEERLESS-HF
(Prospective Evaluation of Elastic Restraint to LESSen the
Effects of Heart Failure). Although the outcomes of this
trial are currently unknown, the few studies on LV restraints
indicate declining interest, possibly due to the invasive
procedure required for this approach.
Cardiac Patches
Initially, cardiac patches involved the use of biomaterial
scaffolds to enhance cell delivery and, more recently, have
been used as an acellular therapy. It is thought that the
microenvironment and architecture provided by such a
scaffold can support cellular differentiation and organiza-
tion, and prevent anoikis (6). Application of various bioma-
terials with a variety of cell types has shown an improvement
in cardiac function in small animals. Nonetheless, 1 major
drawback with this method remains the inability to generate
patches with sizable thickness due to diffusion limitations
(2,6). In the last 5 years, many different scaffolds have been
examined in vitro for such applications (6); however, only in
vivo work is discussed in the following text.
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Biomaterials for the Treatment of MI December 13/20, 2011:2615–29Of the different materials used
for the fabrication of cardiac
patches in recent years, collagen,
the predominant protein in the
extracellular matrix, has been
used extensively, alone and with
cells. Callegari et al. (7) showed
that application of a collagen
sponge to a rat cryoinjury model
immediately post-injury led to
increased angiogenesis, com-
pared with the control, 15 and 60
days post-implantation of the
patch. Additionally, delivery of
human bone marrow–derived
CD133 cells (4  106 cells)
with a collagen scaffold increased
the number of vessels in a rat
cryoinjury model; however, there
was no significant differentiation
nto cardiomyocytes (8). Similarly, application of a collagen
caffold seeded with human mesenchymal stem cells
MSCs) (1 106 cells) immediately post-infarction resulted
n a 30% increase in fractional shortening (FS) in the
atch-treated group compared with the control in a rodent
odel (9). Hamdi et al. (10) compared intramyocardial
elivery of cells with a cardiac patch–based approach.
uman skeletal myoblasts (5  106 cells), control medium,
a bilayer myoblast cell sheet, or a myoblast-seeded collagen
sponge was injected or implanted at the site of infarction, 4
weeks post-MI. Animals that received the cell sheet and
seeded cell scaffold showed significant improvement in
ejection fraction (EF) and increased vessel density compared
with the control, 1 month post-implantation. In theMAGNUM
(Myocardial Assistance by Grafting a New Bioartificial
Upgraded Myocardium) phase 1 clinical trial, a collagen
type I patch seeded with bone marrow cells was applied on
10 patients that had coronary artery bypass graft and
Abbreviations
and Acronyms
bFGF  basic fibroblast
growth factor
ED  end-diastolic
EF  ejection fraction
ES  end-systolic
FS  fractional shortening
LV  left ventricle
MI  myocardial infarction
MSC  mesenchymal stem
cell
PEG  poly(ethylene
glycol)
SIS  small intestinal
submucosa
VEGF  vascular
endothelial growth factor
Figure 1 Biomaterial Approaches to Treatment of MI
There are 3 strategies currently being examined for the treatment of myocardial in
materials. Cardiac patches and injectable materials can be either used as acellula
cules (C and F).intrainfarct implantation of autologous bone marrow cells
(Fig. 2). Both the combined approach of cell injection and
a cardiac patch as well as the cell injection alone showed an
improvement in EF at a 10  3.5 months follow-up
compared with the baseline measurement 1 week before
coronary artery bypass. However, LV ED volume and scar
thickness were improved in the patients that received a
cell-seeded collagen patch combined with cellular injection
compared with those receiving the intrainfarct cell injection
alone (11). Similarly, an improvement in EF was seen in a
mouse MI model upon application of a collagen patch
seeded with human umbilical cord mononuclear cells (5 
106 cells) along with an injection of the same cell type (5 
106 cells) or by the injection of the cells alone 45 days
ost-treatment when compared with the baseline, whereas
eterioration of function was seen in the scaffold-only and
ontrol groups (12).
Giraud et al. (13) showed improvement in FS, 4 weeks
ost-treatment, using a combination patch of collagen type
, Matrigel (BD Biosciences, San Jose, California), and rat
keletal muscle cells adhered on the surface of the heart with
brin glue, 2 weeks post-MI in a rodent model. Similarly,
vir et al. (14) constructed a patch by seeding an alginate
caffold with neonatal cardiomyocytes (7 107 cells/cm3) in
atrigel and pro-survival and angiogenic factors. The patch
as cultured in the rat omentum for 7 days to promote
aturation of vasculature and then transplanted into in-
arcted rats 1 week post-infarction. At 28 days post-
mplantation, this pre-vascularized patch showed structural
nd electrical integration with the host myocardium as well
s preservation of FS and fractional area change. Another
io-derived scaffold, fibrin, has also been seeded with
uman embryonic stem cell–derived endothelial cells (2 
06 cells) and smooth muscle cells (2  106 cells). Implan-
ation in a porcine model immediately post-MI resulted in
mproved EF at 7 days and persisted until 4 weeks (15).
A recent development has been the use of decellularized
rgans for the creation of cardiac patches representing the
n (MI): left ventricular restraints (not shown), cardiac patches, and injectable bio-
folds (A and D), or delivery vehicles for cells (B and E) and/or biological mole-farctio
r scaf
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(16) first demonstrated the ability to decellularize the
myocardium. Godier-Furnémont et al. (17) seeded human
mesenchymal progenitor cells (1  106 cells) in fibrin on a
decellularized human myocardial sheet. Implantation of the
scaffold preserved FS and LV diameter, as well as an
enhanced vascular network, by secretion of paracrine factors
and migration of the MSCs into the damaged myocardium
4 weeks post-treatment in a rat MI model. Similarly,
decellularized small intestinal submucosa (SIS) itself or
seeded with MSCs in a rabbit MI model 4 weeks post-
treatment led to an improvement in LV ES and ED
diameters and EF compared with the control. Furthermore,
animals treated with the MSC-seeded SIS had a signifi-
cantly greater improvement in EF compared with the
animals treated with the SIS alone (18). Likewise, a patch
made with a sliced decellularized pericardial tissue scaffold
inserted with multilayered MSCs was used to replace the
infarcted myocardium in a rodent model, and resulted in
greater FS, higher LV ES pressure, and lower LV ED
pressure when compared with the control (19). Though
there are only limited studies using an organ-derived scaf-
fold in the heart to date, this will likely increase given the
rapidly expanding use of decellularized scaffolds in tissue
engineering.
Along with biologically derived materials, a number of
synthetic materials have been explored. Fujimoto et al. (20)
showed that application of an elastic biodegradable polyester
urethane urea scaffold over a 2-week rodent infarct led to an
increase in regional fractional area change, wall thickness, and
capillary density compared with the control MI group 8 weeks
post-implantation. Siepe et al. (21,22) generated a scaffold by
seeding rat skeletal myoblasts on a highly porous polyurethane
scaffold. After implantation, 2 weeks post-MI, in a rat model,
there was evidence that both themuscle grafts and the injection
of skeletal myoblasts alone led to improved contractile function
and increased EF 4 weeks post-implantation, compared with
the acellular scaffold group and the control. In a follow-up
long-term study, prevention of heart failure was seen up to 9
months; however, this diminished by 12 months, indicating
such a therapeutic approach may have transient benefit (23).
Piao et al. (24) implanted biodegradable poly(glycolide-co-
caprolactone) with or without bone marrow–derived mononu-
clear cells 7 days post-infarction in a rat. Four weeks post-
implantation, there was improved FS, LV ED pressure, and
LV ED and ES diameters in both scaffold groups compared
with the sham-operated group. Another study compared the
effectiveness of direct cell injection versus a cardiac patch–
based approach. MSCs (1  106 cells) were directly trans-
planted into the border of a cryoinjury infarct or seeded onto
poly(lactide-co--caprolactone) and implanted over the in-
farct area 10 days post-MI. EF increased by 23% and the
infarct area decreased by 29% in the polymerMSC group
compared with saline and the acellular scaffold, 4 weeks
post-treatment. Similar results were seen in the MSC-only
group (25).Injectable Biomaterials
Over the last 5 years, there has been extensive growth in the
field of injectable biomaterials for treating MI. These
materials have been injected alone or used as delivery
vehicles for cells and/or biological moieties. Injectable ma-
terials have shown positive results such as improvement in
cardiac function, reduction of infarct size, and increase in
neovascularization. It is now well established that delivery of
cells in a biomaterial can improve cellular retention and
viability. Given the promise of this approach, materials have
advanced to large-animal pre-clinical models and even early
clinical trial stage (26). Most notably, materials such as
alginate and myocardial matrix have gelation properties that
facilitate percutaneous delivery into the myocardium (27–29),
alleviating the need for invasive procedures required for the
application of LV restraints and cardiac patches.
Proof of concept for the ability of injectable biomaterials
alone to preserve cardiac function post-MI and to improve
cell transplant survival was first demonstrated with fibrin in
a rat ischemia-reperfusion model (30,31). This initial study
utilized skeletal myoblasts, and these results have since been
confirmed with a variety of cell types such as bone marrow
cells (32), marrow-derived cardiac stem cells (33), and
adipose-derived stem cells (34,35). In some studies, fibrin
alone caused improvement in function similar to that of
injection of fibrin with cells, whereas in others cases, an
enhancement of cardiac function was seen by adding cells to
the biomaterial. The reason for the discrepancy is unclear,
but it could be due to the difference in the rat MI models
used. Injection of cells may provide additional value com-
pared with acellular injection; however, to date, many
studies show similar improvements in cardiac function with
a biomaterial alone. Basic fibroblast growth factor (bFGF)
in fibrin (36), hepatocyte growth factor in a pegylated fibrin
(37), and transforming growth factor -1 in poly(lactic-
co-glycolic acid) microspheres and bone marrow mononu-
clear cells in a fibrin gel (38) have also been explored for
treatment of MI. In a pig model, direct microinjections of a
fibrin-alginate composite in the infarct, 1 week post-MI
preserved wall thickness and decreased infarct expansion 7
days post-injection (39). One potential concern with fibrin,
however, is the 2-component system made of fibrinogen and
thrombin, making minimally invasive delivery a challenge.
The pivotal work done in 2005 by Leor et al. (40) has
paved the way for the use of alginate as a scaffold for
myocardial tissue engineering for injection alone or as a
scaffold for growth factor or cell delivery. In the last 5 years,
major progress has been made with this seaweed-derived
polysaccharide. Landa et al. (41) showed that injection of
alginate at 1 week in a rat MI resulted in increased scar
thickness and improved LV ES and ED area compared with
saline 2 months post-injection. These results were similar or
superior to injection of neonatal cardiomyocytes. At 6 weeks
post-injection, the biomaterial was degraded, thus the
increase in wall thickness was potentially due to infiltrating
5-Year Update on Biomaterials for the Treatment of MITable 1 5-Year Update on Biomaterials for the Treatment of MI
2006–2011 Prior to 2006*
Material Transplantation Model Ref. # Transplantation Model
LV restraints
Polypropylene — — — Alone Sheep
Polyester Alone Sheep (84) Alone Dog, sheep, human
Nitinol Alone Dog, sheep, human (3–5) — —
Cardiac patch
Gelatin — — — Alone
w/Fetal CM
Rat
Alginate — — — w/Fetal CM Rat
Poly(glycolide)/poly(lactide) — — — w/Dermal fibroblasts Mouse
PTFE, PLA mesh, collagen type I
and matrigel
— — — Alone
w/Bone marrow–derived mesenchymal progenitor cells
Rat
PTFE — — — Alone Pig
Collagen type I and Matrigel w/SkM Rat (13) w/Neonatal CM Rat
Collagen type I Alone
w/BMC, HUCBCs, hBMC CD133, hMSC, hSkM
Rat, human, mouse (7–12) Alone
w/ESC
Rat
Alginate and Matrigel w/SDF-1, IGF-1 and VEGF
w/Neonatal CM  SDF-1, IGF-1 and VEGF
Rat (14) — —
Chitosan — — — Alone w/FGF-2 Rabbit
Fibrin Alone
w/hESc-derived ECs and hESC-derived SMCs
Pig (15) — —
Polyurethane Alone
w/SkM
Rat (21,22) — —
Polyester urethane urea Alone Rat (20) — —
Poly(glycolide-co-caprolactone) Alone
w/BMMNC
Rat (24) — —
Poly(lactide-co--caprolactone) Alone
w/MSCs
Rat (25) — —
Decellularized myocardium/fibrin w/Mesenchymal progenitor cells Rat (17) — —
Small intestinal submucosa Alone
w/MSCs
Rabbit (18) — —
Pericardium w/MSCs Rat (19) — —
Urinary bladder matrix — — — Alone Pig
Injectable biomaterials
Fibrin Alone
w/BMCs, ASCs, MCSCs, BMMNCs
w/bFGF, HGF, TGF-1
Mouse, rat, dog (32–38) Alone
w/SkM, BMMNCs
w/Pleiotrophin plasmid
Rat, sheep
Alginate Alone, RGD modified, RGD YIGSR modified,
RGE modified
w/VEGF, PDGF-BB, IGF-1, HGF
w/hMSCs
w/Polypyrrole
Rat, pig, human (26,29,41–47) Alone Rat
Fibrin -Alginate Alone Pig (39) — —
Continued on next page
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ContinuedTable 1 Continued
2006–2011 Prior to 2006*
Material Transplantation Model Ref. # Transplantation Model
Chitosan Alone
w/ESCs
w/bFGF
Rat (54–56) — —
Gelatin Alone
w/bFGF
Rat, dog (57,58) w/bFGF Rat
Collagen — — — Alone
w/BMCs
Rat, pig
Matrigel Alone
w/hESC derived CMs
w/pro-survival factors
Rat (59,60) Alone
w/ESCs
Mouse, rat
Collagen type I and Matrigel — — — Alone
w/Neonatal CMs
Rat
Small intestinal matrix Alone Mouse, rat (48,49) — —
Myocardial matrix Alone Rat, pig (28,51) — —
Pericardial matrix Alone Rat (52) — —
Hyaluronic acid Alone Rat, sheep (76,77) — —
Self-assembling peptides Alone
w/SkM  PDGF-BB, BMMNCs
w/IGF-1, PDGF-BB, FGF-2
Rat, pig (78–81) Alone
w/Neonatal CM
w/PDGF-BB
Mouse, rat
Calcium hydroxyapatite Alone Sheep (61,62) — —
PEG based Alone
w/BMSC, hESC  thymosin 4
w/VEGF, thymosin 4, erythropoietin
Rat, rabbit (63,67,68,70,71,74,75) — —
PNIPAAm based Alone
w/BMMNCs, BMSC
w/bFBF
Rat, rabbit (64–66,69,72) — —
This table is modified in part from Christman and Lee (2). *All references for studies prior to 2006 can be found in Christman and Lee (2).
ASC adipose-derived stem cell; bFGF basic fibroblast growth factor; BMC bone marrow cell; BMMNC bone marrow–derived mononuclear cell; BMSC bone marrow–derived stem cell; CM cardiomyocyte; ECendothelial cell; ESC embryonic stem cell; FGF
fibroblast growth factor; HGF  hepatocyte growth factor; HUCBC  human umbilical cord blood mononuclear cell; HUVEC  human umbilical vein endothelial cell; IGF  insulin-like growth factor; MCSC marrow-derived cardiac stem cell; MSC mesenchymal stem cell;
PCL polycaprolactone; PDGF platelet-derived growth factor; PEG poly(ethylene glycol); PLA polylactic acid; PNIPAAM poly(N-isopropylacrylamide); PTFE polytetrafluoroethlyene; SDF stromal cell–derived factor; SkM skeletal myoblast; TGF transforming
growth factor; VEGF  vascular endothelial growth factor.
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Cardiac Function Data From Select PublicationsTable 2 Cardiac Function Data From Select Publications
Material
MI
Model Cells/Biological Molecules
Time Point of
Treatment
After MI
Time Point of
Assessment
Post-Treatment Selected Results Ref. #
LV restraints
Nitinol Sheep — Immediate 6 weeks Reduction in LV ED volume index (device: 0.20 0.41 vs. control:
0.83 0.50 ml/kg) and ES volume index (device: 0.43 0.28 vs.
control: 0.90 0.38 ml/kg) in treatment group compared with the
control.
(3)
Cardiac patch
Collagen Human Autologous bone marrow cells
(250  106 cells)
— 10 3.5 months Improvement in EF at follow-up compared the baseline measurement
1 week before coronary artery bypass in cell injection  cardiac
patch (25.3  7.3% to 32  5.4%) and cell injection alone (27.2 
6.9% to 34.6  7.3%) groups. LV ED volume (patch: 142.4 24.5 ml
to 112.9 27.3 ml, cell injection: 138.9 36.1 ml to 148.7 41
ml) and scar thickness were improved in the patients that received a
cell-seeded collagen patch combined with cellular injection compared
with those receiving the cell injection alone.
(11)
Collagen  Matrigel Rat Rat skeletal muscle cells
(1  106 cells)
2 weeks 4 weeks Increased FS using a combination patch of collagen type I, Matrigel, and
cells compared with baseline (patch: 33  5% to 42  6%).
(13)
Small intestinal submucosa Rabbit MSCs (1  106 cells) 4 weeks 4 weeks Improvement in LV ES diameter (patch  cells: 11.14 1.06 mm,
patch: 13.12 1.61 mm, control: 14.98 1.19 mm), LV ED
diameter (patch  cells: 13.89 1.11 mm, patch: 15.21 1.46
mm, control: 18.76 2.24 mm), and EF (patch  cells: 40.52 
1.50%, patch: 37.34  2.51%, control: 30.53 3.58 %) with an
acellular or cell-seeded patch compared with the control. Treatment
with cell-seeded patch led to significantly greater EF compared with
acellular patch.
(18)
Decellularized pericardium Rat MSCs (1.5  106 cells) 4 weeks 12 weeks Higher FS (patch: 37.6 4.7 %, control: 16.6 3.7%, sham 54.3 3.9%),
and greater LV ES pressure (patch: 105.3 8.7 mm Hg, control:
71.4 11.5 mm Hg, sham: 112.3 3.8 mm Hg) and lower LV ED
pressure (patch: 6.8 1.7 mm Hg, control: 18.9 3.9 mm Hg,
sham: 4.6 0.8 mm Hg) after treatment with MSC-layered
pericardial patch when compared with the control.
(19)
Polyester urethane urea Rat — 2 weeks 8 weeks Improvement in wall thickness, capillary density, and regional fractional
area change in the patch-implanted group compared with the control
(patch: 27 9.0% vs. control: 15 10%).
(20)
Polyurethane Rat Rat skeletal myoblasts
(5  106 cells)
2 weeks 4 weeks Improved contractile function and EF in the cell-seeded scaffold and cell
injection alone compared with the acellular scaffold group and the
control (patch  cells: 48.4  3.1%, cells: 47.9  3.0%, patch:
39.6  1.8% control: 40.1  4.1%).
(21,22)
Poly(glycolide-co-caprolactone) Rat Bone marrow–derived
mononuclear cells
(2  106 cells)
1 week 4 weeks Enhanced FS (patch  cells: 32.5  8.6%, patch: 31.8  11.9%, sham:
15.6  4.3%), LV ED diameter (patch  cells: 8.6 0.6 mm, patch:
8.7 0.8 mm, sham: 11.1 0.5 mm), LV ES diameter (patch 
cells: 5.8 0.9 mm, patch: 6.0 1.6 mm, sham: 9.4 0.4 mm),
and LV ED pressure (patch  cells: 2.5 2.3 mm Hg, patch:
12.3 0.6 mm Hg, sham: 11.4 3.8 mm Hg) in scaffold alone and
cell-seeded scaffold groups compared with the sham-operated group.
(24)
(Continued on next page)
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ContinuedTable 2 Continued
Material
MI
Model Cells/Biological Molecules
Time Point of
Treatment
After MI
Time Point of
Assessment
Post-Treatment Selected Results Ref. #
Injectable materials
Fibrin Rat Marrow-derived cardiac stem cells
alone (5  106 cells)
1 week 3 weeks Improved EF in all groups compared to the control (fibrin  cells: 70.77 2.45%, cells:
55.96 2.56%, fibrin: 47.62  3.97% and control: 35.25 3.21 %). However greatest
improvement was seen in the cells  fibrin injected animals.
(33)
Fibrin Rat Adipose-derived stem cells
(5  106 cells)
1 week 4 weeks Improved EF (fibrin  cells: 61.77  4.14%, cells: 55.75  3.41%, fibrin: 53.14  3.59%,
control: 38.80  2.91%), LV ED diameter (fibrin  cells: 5.91 0.24 mm, cells:
6.80 0.38 mm, fibrin: 6.70 0.41 mm, control: 7.66 0.30 mm), LV ES diameter
(fibrin  cells: 4.24 0.26 mm, cells: 5.04 0.22 mm, fibrin: 5.24 0.35 mm,
control: 6.50 0.20 mm) with injection of fibrin  cells compared with injection of
acellular fibrin or cells alone. All groups showed improvement compared with the saline
control.
(35)
Alginate Rat — 1 week 2 months Improved LV systolic area (alginate: 0.56 0.05 cm2, cells: 0.59 0.06 cm2, control:
0.76 0.04 cm2) and diastolic area (alginate: 0.32 0.04 cm2, cells: 0.38 0.06 cm2,
control: 0.51 0.04 cm2) in animals injected with alginate alone or with an
intramyocardial injection of neonatal cardiomyocytes (1  106) compared with the
saline control.
(41)
Alginate Rat RGD, human MSCs
(0.4  106 cells)
1 week 10 weeks Preservation of wall thickness and LV internal diameter as well as improvement in FS
with injection of RGD-modified alginate microbeads with and without human MSCs
compared with baseline (alginate microbeads: 30.5  8.3% to 33.9  9.1%, cells in
microbeads: 27.3  7.1% to 32.0  9.8%, control: 28.4  6.7% to 21.1%  10.7%).
(45)
Alginate Rat RGD and YIGSR 1 week 60 days Improvement of scar thickness and FS with unmodified alginate compared to alginate
modified by RGD and YIGSR or the control RGE peptide (alginate: 34.45  5.4%,
alginate  RGD/YIGSR: 21.63  3.66%, alginate  RGE: 19.59  3.04%, control:
16.45  1.98%).
(46)
Alginate Pig — 3–4 days 30 days, 60 days Increased LV diastolic area compared with baseline (% change: alginate [1 ml]: 20  17%,
alginate [2 ml]: 1  2%, alginate [4 ml]: 6  4%, control: 44  8%) and systolic
area (% change: alginate [1 ml]: 1.6  8%, alginate [2 ml]: 13  4%, alginate [4 ml]:
9  10%, control: 45  24%) as well as LV mass in the control animals, whereas
injection of 2 ml or 4 ml of alginate led to preservation or improvement in LV area.
Injection of 2 ml of alginate increased scar thickness by 53% compared with the saline
control.
(29)
Small intestinal submucosa Mouse — Immediate 2 weeks, 6 weeks Improvement in LV ES area (2 weeks, SIS-B: 5.8 0.1 mm2, SIS-C: 7.0 0.4 mm2,
control: 6.7 0.6 mm2; 6 weeks, SIS-B: 5.7 0.3 mm2, SIS-C: 6.9 0.3 mm2, control:
6.7 0.3 mm2) and fractional area change (2 weeks, SIS-B: 34.8%  1.1%, SIS-C:
24.9  2.8%, control: 25.6  1.9%; 6 weeks, SIS-B: 31.5  0.8%, SIS-C: 24.7  1.5%,
control: 24.1%  1.9%) with SIS-B compared with SIS-C and the control at 2 weeks
post-treatment, but not at 6 weeks. SIS-B–injected hearts demonstrated infarct size
reduction and increased capillary density compared with SIS-C and the control only at
6 weeks after treatment.
(49)
Chitosan Rat Undifferentiated nuclear-transferred
embryonic stem cells
(1  107 cells)
1 week 4 weeks Improvement in EF (chitosan  cells: 63.6  4.3%, cells: 57.9  4.9%, chitosan: 56.8 
2.7%, control: 33.1  3.0%), LV ED diameter (chitosan  cells: 7.2 0.3 mm, cells:
7.8 0.3 mm, chitosan: 7.3 0.4 mm, control: 8.5 0.2 mm) and LV ES diameter
(chitosan  cells: 5.1 0.2 mm, cells: 5.8 0.4 mm, chitosan: 5.9 0.3 mm, control:
7.5 0.2 mm) with cells in chitosan compared with the acellular scaffold, cell
transplantation alone, or saline control.
(54)
(Continued on next page)
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ContinuedTable 2 Continued
Material
MI
Model
Cells/Biological
Molecules
Time Point of
Treatment
After MI
Time Point of
Assessment
Post-Treatment Selected Results Ref. #
Matrigel Rat — Immediate 4 weeks Increased infarct wall thickness, capillary density, and c-Kit cells, as well as improved EF,
with injection of Matrigel when compared with the saline control (Matrigel: 42.72 
1.45%, control: 34.81  2.03%),
(59)
Matrigel Rat Human embryonic
stem cell–derived
cardiomyocytes
(10  106 cells) in
a multicomponent
pro-survival cocktail
4 days 4 weeks Improved LV ES diameter (cardiomyocytes  pro-survival cocktail: 5.8 0.2 mm, pro-survival
cocktail: 7.7 0.3 mm, media: 8.0 0.1 mm, noncardiac cells  pro-survival cocktail:
7.3 0.5 mm) and EF (cardiomyocytes  pro-survival cocktail: 50.3  2%, pro-survival
cocktail: 45  1.6%, media: 42  1.9%, noncardiac cells  pro-survival cocktail: 43 
4%) with injection of differentiated human embryonic stem cell–derived cardiomyocytes in
the Matrigel-containing pro-survival cocktail compared with the survival cocktail alone,
media alone, or in the case of LV systolic diameter, the “noncardiac” human embryonic
stem cell–derived cells.
(60)
Calcium hydroxyapatite Sheep — 3 h 8 weeks Enhancement of EF (calcium hydroxyapatite: 31.3  2.6%, control: 27.6  1.3%), LV ES
volume (calcium hydroxyapatite: 60.8 4.3 ml, control: 80.3 6.9 ml), LV ED volume
(calcium hydroxyapatite: 87.2 4.0 ml, control: 110.6 8.4 ml), as well as a decrease in
infarct expansion and longitudinal strain, after calcium hydroxyapatite treatment
compared with the control.
(61)
Calcium hydroxyapatite Sheep — 45 min 4 weeks Improvement in EF (calcium hydroxyapatite: 37.3  1.7%, control: 29.5  1.6%) and LV ES
volume (calcium hydroxyapatite: 44.5 3.9 ml, control: 61.2 3.6 ml) with calcium
hydroxyapatite compared with the control.
(62)
Poly(N-isopropylacrylamide-
co-propylacrylic acid-
co-butyl acrylate)
(p[NIPAAm-co-PAA-co-BA])
Rat bFGF Immediate 4 weeks Increase in vessel density (30% to 40%) and FS in the hydrogel  bFGF group compared to
the hydrogel alone and bFGF control (hydrogel  bFGF: 30 1.4%, hydrogel: 25 1.2%,
control: 25 1.8%).
(69)
PEG Rat EPO Immediate 30 days Improvement in FS (PEG  EPO: 26.93  2.49%, PEG: 22.53  3.21%, EPO: 21.98 
3.04%, control: 19.57  4.20%), LV ED diameter (PEG  EPO: 7.4 0.4 mm, PEG:
8.51 0.70 mm, EPO: 8.85 0.72 mm, control: 10.33 0.78 mm) and LV ES diameter
(PEG  EPO: 5.48 0.51 mm, PEG: 6.61 0.80 mm, EPO: 6.85 0.58 mm, control:
8.22 1.01 mm) with injection of the PEG  EPO gel compared with the polymer alone
and EPO alone. However, all groups demonstrated improvement compared with the saline
control.
(70)
PEG Rat — Immediate 4 weeks,
13 weeks
Increase in wall thickness and reduction in LV ED diameter with PEG compared with the
saline control at 4 weeks, but effect was diminished by 13 weeks (4 weeks, PEG:
8.5 0.2 mm, control: 9.2 0.2 mm, 13 weeks, PEG: 10.2 0.3 mm, control:
10.2 0.3 mm).
(74)
PEG Rat — 1 week 6 weeks Increase in wall thickness with PEG; however, a decrease in EF (PEG: 44.20  8.52%, control:
42.96  6.58%), as well as an increase in LV ED volume (PEG: 487.1 109.9 mm3, control:
502.6 131.1 mm3) and LV ES volume (PEG: 282.6 104.2 mm3, control:
288.8 102.3 mm3), in both PEG- and saline-injected animals.
(75)
Hyaluronic acid and PEG Rat — 2 weeks 4 weeks Improvement in EF (hyaluronic acid: 42.74  7.53%, control: 18.17  5.42%, sham: 48.50
 8.02%) and elastance in hyaluronic acid  PEG group compared towith the control.
(77)
Peptide nanofibers Mini pigs Bone marrow
mononuclear cells
(1  108 cells)
Immediate 1 month Improvement in LV ES volume (nanofiber  cells: 51.7 4.6 ml, cells: 58.7 2.4 ml,
nanofibers: 73.7 3.6 ml, control: 103.0 7.0 ml), and LV ED volume (nanofiber  cells:
113.6 6.1 ml, cells: 115.0 5.7 ml, nanofibers: 120.3 7.0 ml, control: 147.5 7.0 ml) in
all groups compared with the control.
(80)
bFGF  basic fibroblast growth factor; ED  end diastolic; EF  ejection fraction; EPO  erythropoietin; ES  end systolic; FS  fractional shortening; LV  left ventricle; MI  myocardial infarction; MSC  mesenchymal stem cell; PEG  poly(ethylene glycol).
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infarcts (8 weeks) and assessed 2 months later, showing a
similar increase in scar thickness and improvement in
systolic and diastolic function. Delivery of vascular endo-
thelial growth factor (VEGF) as well as sequential delivery
of VEGF followed by platelet-derived growth factor (42) or
insulin-like growth factor and hepatocyte growth factor (43)
in alginate showed improvement in LV remodeling com-
pared with the biomaterial alone and the control 4 weeks
post-injection in a rat MI. The effects of surface modifica-
tion of alginate was also studied by injection of alginate
modified with RGD or unmodified alginate 5 weeks
post-MI into a rat LV aneurysm model. Improvement in
LV ES and ED diameter as well increased arteriole presence
was observed in both groups compared with saline (44).
Injection of RGD-modified alginate microbeads with and
without human MSCs in a 1-week rodent MI led to
improvement in FS and preservation of wall thickness and
LV internal diameter 10 weeks post-injection (45). Con-
trary to these studies, Tsur-Gang et al. (46) showed that
modification of alginate by RGD and YIGSR or the control
RGE peptide was not as effective as unmodified alginate in
improvement of scar thickness and FS, 60 days post-
injection into a 1-week rat infarct. It is hypothesized that this
discrepancy could be due to alteration in viscosity upon
addition of the peptides that led to changes in distribution of
the material and reduced coverage of the infarct. In addition,
alginate has been blended with the electroactive polymer
polypyrrole showing an increase in arteriole density 5 weeks
post-treatment compared with alginate alone and saline upon
Figure 2 Clinical Case From the MAGNUM Trial
A human heart treated with a bone marrow cell–seeded collagen matrix patch
after coronary artery bypass graft and cell injection. Reprinted, with permission,
from Chachques et al. (11).injection in a rat MI (47). Leor et al. (29) carried outpre-clinical work with alginate in a swine MI model showing
that intracoronary injection of alginate led to prevention and
reversal of negative LV remodeling. Saline-injected animals
had an increase in LV ED and ES area as well as LV mass,
however injection of 2 ml or 4 ml of alginate led to
preservation or improvement in LV area, but not FS. The
2-ml injection increased scar thickness by 53% compared
with saline, possibly due to myofibroblast migration and
deposition of collagen (Fig. 3) (29). These results have
recently led to a first-in-man safety and feasibility study of
intracoronary injection of alginate in acute MI patients (26).
As with cardiac patches, the use of decellularization as a
technique for preparation of injectable materials is growing
at a rapid pace. Injection of decellularized SIS extracellular
matrix into an ischemia-reperfusion rat model promoted cell
migration (c-kit cells, myofibroblasts, and macrophages)
and improvement in cardiac function in terms of EF and
stroke volume compared with the saline control (48). Okada et
al. (49) injected 2 forms of SIS-derived gels immediately
post-MI in a murine model. One form, SIS-B, improved LV
ES area and fractional area change compared with SIS-C and
the control at 2 weeks post-treatment, but not at 6 weeks.
However, SIS-B reduced infarct size and increased capillary
density compared with SIS-C and the control, only at 6 weeks.
These differences are potentially attributed to increased bFGF
content and greater stiffness of the gel. Although general
extracellular matrix components among tissues are similar,
heterogeneity exists in the combination of proteins and pro-
teoglycans (50). Given the complex extracellular structure of
the heart, the injection of a cardiac-specific matrix may be
better suited for treating the myocardium. Singelyn et al. (51)
developed an injectable hydrogel form of decellularized porcine
ventricular tissue, which was first tested in healthy myocar-
dium. More recently, it was shown that this material preserved
cardiac function in a rat MI model and is compatible with
percutaneous transendocardial delivery in pigs (28). Seif-
Naraghi et al. created and injected an acellular pericardial
matrix gel into healthy rodent myocardium as proof-of-
concept for a potentially autologous therapy for MI (52) and
has also demonstrated that this material can be formed from
samples from a variety of human patients (53). The pericardial
matrix induced neovascularization and the recruitment c-kit
cells (52).
A few other bio-derived materials have been examined for
treating MI. Chitosan, a naturally occurring polysaccharide
derived from crustacean shells, was injected with undiffer-
entiated embryonic stem cells 1 week post-MI, resulting in
improvement in EF and LV ED and ES diameters com-
pared with the acellular scaffold, cell transplantation alone,
or saline in a rodent MI model 4 weeks post-injection
(54,55). The co-injection of a chitosan with bFGF im-
proved EF, FS, LV diameters, and arteriole density, as well
as decreased infarct size and fibrotic area compared with the
injection of bFGF alone 4 weeks post-transplantation in a
rodent MI (56). Similarly, gelatin with bFGF has shown
improvements in cardiac function in both small (57) and
2624 Rane and Christman JACC Vol. 58, No. 25, 2011
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post-infarction led to increased infarct wall thickness, im-
proved EF, as well as increased capillary density and c-Kit
cells, when compared with saline in a rat MI model, 4 weeks
post-injection (59). Laflamme et al. (60) injected human
embryonic stem cell–derived cardiomyocytes in a multicom-
ponent pro-survival cocktail containing Matrigel in a rat
occlusion-reperfusion model 4 days post-MI. After 4 weeks,
the pro-survival factors resulted in significantly increased
cell survival. In addition, injection of this combination led to
attenuation of LV remodeling post-MI as demonstrated by
reduced ventricular dilation, improved global cardiac func-
tion, and increased wall motion. In addition, delivery of
acellular calcium hydroxyapatite into an ovine MI model led
to improvement in EF and LV volume compared with the
control 4 weeks and 8 weeks post-MI as well as a decrease
in infarct expansion and longitudinal stain (61,62).
In the past 5 years, synthetic injectable polymers have
begun to be examined as a treatment for MI. In contrast to
biologically derived materials, synthetic materials allow for
control over properties such as degradation, stiffness, poros-
ity, and gelation time, and do not suffer from the batch-to-
batch variability that occurs with bio-derived materials. A
matrix metalloproteinase–degradable poly(ethylene glycol)
(PEG) loaded with thymosin -4 and endothelial (0.66 
106 cells) and smooth muscle-like (0.33  106 cells) cells
derived from human embryonic stem cells improved EF and
ED and ES volumes, as well as decreased infarct size and
increased vessel density, compared with the control (63). A
Figure 3 Intracoronary Alginate Injection
Brown staining indicates alginate gelled inside porcine myocardium. Reprinted, witsimilar result was seen with injection of degradable poly(N-isopropylacrylamide)-based (64–66) and PEG-based (67,68)
gels with or without cells in a MI. Garbern et al. (69)
injected a pH- and temperature-responsive hydrogel loaded
with bFGF immediately post-MI in a rat and showed a 30%
to 40% increase in vessel density as well as an increase in FS
compared with the hydrogel alone and bFGF injected in
saline 28 days post-treatment. Similarly, delivery of eryth-
ropoietin with a PEG-based gel into a rat immediately
post-MI led to an improvement in FS and LV ED and ES
diameters compared with injection of polymer alone and
erythropoietin alone; however, all groups demonstrated
improvement compared with saline, 30 days post-MI (70).
Along the same lines, VEGF was either mixed or conju-
gated to a hydrogel for delivery into a rat 1 week post-MI.
At 35 days post-injection, EF, ED and ES volumes, scar
thickness, and vessel density were improved in the group in
which the VEGF was tethered to the hydrogel when
compared with the animals injected with unconjugated
VEGF, hydrogel alone, and saline (71), thus indicating that
tethering growth factors to biomaterials can lead to greater
beneficial effects. Poly(NIPAAM-co-acrylic acid) hydrogels
with matrix metalloproteinase degradable crosslinkers were
used to transplant bone marrow–derived mononuclear cells
(2 105 cells) into infarcted mouse myocardium. However,
injection of the material alone led to the greatest improve-
ment in EF (72). In the past, Wall et al. (73) used
computational modeling to suggest that the presence of a
material alone at the site of infarction may lead to an
improvement in cardiac function due to an increase in wall
ission, from Leor et al. (29).h permthickness leading to a subsequent decrease in wall stress due
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gradable material on pathological remodeling, Dobner et al.
(74) injected a nondegradable PEG hydrogel immediately
post-MI in a rat model. Although LV ED diameter was
reduced and wall thickness was increased at 4 weeks, by 13
weeks, pathological progression was similar to that of
saline-injected animals. Similarly, Rane et al. (75) showed
that even after injection at the clinically relevant time point
of 1 week post-MI in a rat, increase in wall thickness alone
by injection of a bio-inert PEG was insufficient to prevent
the downward spiral of LV remodeling. PEG-injected
animals showed a decline in EF and LV ED and ES
volumes similar to that of saline, 7 weeks post-MI. These
results suggest that inherent bioactivity and/or material
degradation allowing for cell infiltration may be the mech-
anisms by which injectable materials affect cardiac function.
Material properties of injectable biomaterials have recently
come under investigation; Ifkovits et al. (76) examined the
effect of material stiffness on cardiac function and LV
remodeling in an ovine MI model. Methacrylated hyal-
uronic acid was tailored to a stiffness of 8 kPa and 43 kPa,
and injected into the infarct 30 min post-MI. Although
there were no significant differences in functional parame-
ters, infarct area was reduced in the group injected with a
stiffer hydrogel at 8 weeks (76). Another study injected a gel
comprised of hyaluronic acid and PEG in a 2-week rodent
MI and showed a clear improvement in EF and elastance
compared with the control animals 4 weeks post-treatment
(77). However, the stiffness of the gel was not measured, so
it is difficult to compare the results of this study with those
of Ifkovits et al. (76).
Bio-inspired self-assembling peptide nanofibers have
been used as a platform for cell and growth factor delivery in
both small (78,79) and (80) large animals. Davis et al. (78)
demonstrated that tethering insulin-like growth factor-1 to
peptide nanofibers along with neonatal cardiomyocytes (5
105 cells) improved systolic function in a rat MI 21 days
ost-infarction compared with untethered growth factor.
ollowing this study, Lin et al. (80) injected mini pigs with
utologous bone marrowmononuclear cells, peptide nanofibers
1% in saline), or a combination of both at the site of infarction
mmediately post-MI (Fig. 4). Injection of cells with the
anofibers improved both diastolic and systolic function. Most
ecently, self-assembling peptides were utilized for dual deliv-
ry of platelet-derived growth factor and fibroblast growth
actor 2 into a rat infarct, showing reduction in infarct size in
ddition to an increase in capillary and arteriole density at 4
nd 8 weeks post-MI (81).
uture Directions
ver the last 5 years, there has been a rapid increase in new
ublications in the field of cardiac biomaterials. Although
any investigated materials remained the same over the last
ecade, in recent years, new materials have been developed
or myocardial tissue engineering, most notably synthetic aaterials and decellularized extracellular matrices. Many of
he materials initially studied continue to be investigated in
onjunction with different cell types and biological mole-
ules. Remarkably, most studies have led to an improvement
n cardiac function and neovascularization.
One concern, however, is the contradictory results seen in
any cardiac patch studies. Piao et al. (24) showed that
one marrow mononuclear cells seeded on a degradable
oly-glycolide-co-caprolactone scaffold and the acellular
caffold reduced LV dilation and preserved LV systolic
unction. Similar results were seen after applying a degrad-
ble polyester urethane urea cardiac patch (20). Contrary to
he aforementioned results, Jin et al. (25) showed that
mplantation of polylactide-co--caprolactone alone was
ot able to improve EF or decrease infarct size. The reason
or this is not clear, but could be attributed to differences in
xperimental conditions. Further studies are needed to
nderstand the efficacy of acellular patches versus cell-
eeded implants and the benefits and drawbacks of synthetic
ersus bio-derived scaffolds. In the case of a synthetic
egradable scaffold, the scaffold functions as a temporary
upport for the cells before they integrate into the host
yocardium. The material properties of synthetic materials
an be modulated to attain elastic properties suitable for the
eart’s dynamic environment and may also temporarily alter
he mechanical environment and reduce wall stress. On the
ther hand, a biologically active scaffold can provide a
uitable microenvironment in addition to serving as a
upport. For instance, Tan et al. (18) demonstrated that an
IS graft seededwithMSCswasmore effective than the SIS graft
lone, though both patches were able to improve LV
ontractile function, dimension, and capillary density. A
eeper fundamental understanding of the mechanisms gov-
rning the improvement in cardiac function seen with patch
mplantation may allow for further insight into the materials
nd/or cells best suited for this therapy.
In the last 2 years, there has been an emphasis on
nderstanding the mechanisms responsible for improve-
ent in cardiac function seen with injectable biomaterials.
fkovits et al. (76) studied the effect of changing material
echanics, showing injection of stiffer materials to be
eneficial for reducing infarct size, whereas other studies
ave assessed the impact of structural reinforcement on LV
unction (74,75). Until recently, it was thought that an
ncrease in wall thickness alone by injectable materials or
ardiac patches can lead to a decrease in wall stress,
reventing infarct expansion and negative LV remodeling.
owever, studies have shown that this is not sufficient for
ong-term improvement in function (69,74,75). This could
ossibly be due to nonuniformity in polymer spread allow-
ng for regional and global abnormalities in function, as well
s infarct expansion in areas where the polymer has not
ocalized. Further studies are needed to fully understand the
ffects of polymer spread and stiffness on infarct expansion
nd deterioration of cardiac function.
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important role in cardiac pump function. Ventricular twist is
conserved among species, making it an important parameter
to extrapolate data among small animals, large animals, and
humans (82). To date, limited studies (61,83,84) have
investigated the effect of biomaterial therapies on important
clinical parameters such as cardiac strain, twist, and torsion.
Additionally, very few groups have studied the electrical
integration of cells that have been implanted in or migrate
into a scaffold (14). As seen with the transplantation of cells
Figure 4 Injection of Peptide NFs With Autologous MNCs in Po
MI  myocardial infarction; MNC  bone marrow mononuclear cell; NF  nanofibe(85), arrhythmia vulnerability due to injectable materialsand cardiac patches is a valid and understudied concern. In
the MAGNUM phase I clinical trial, there was no increase
in proarrhythmic events or incidence of ventricular tachy-
cardia post-implantation of a collagen scaffold with bone
marrow cells (11). However, this study was performed on a
small cohort of patients, so the issue of arrhythmogenicity
needs to be further investigated for all biomaterial MI
therapies prior to human translation.
Most of the biomaterials that have been examined are
degradable, with the degradation rate ranging from 1 to 6
MI Model
 saline. Reprinted, with permission, from Lin et al. (80).rcine
rs; NSweeks for most injectable biomaterials. After MI, collagen
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structural reinforcement (86). Although biomaterials may
function as a structural support at early time points to
prevent wall thinning, the timely degradation of these
polymers may allow for cellular infiltration. These cells may
be advantageous for changing the infarct milieu by increas-
ing neovascularization, modulating the inflammatory re-
sponse, and/or generating other positive paracrine factors.
An exciting development over the last 5 years is the
beginning of clinical translation of cardiac patches and
injectable materials. The safety and feasibility of collagen
cardiac patches was demonstrated in the MAGNUM phase
I clinical trial (11). As with LV restraint devices, one
drawback of cardiac patches is the invasive procedure
required for these approaches. In contrast, some injectable
materials can be injected minimally invasively using catheter
delivery (27). Alginate has been delivered in a small phase I/II
study in acute MI patients (26), and will be further examined
in the phase II PRESERVATION I (IK-500 for the Preven-
tion of Remodeling of the Ventricle and Congestive Heart
Failure After Acute Myocardial Infarction) trial. The myocar-
dial matrix hydrogel has also been delivered via catheter and
shown to improve EF in a porcine MI model (data unpub-
lished), demonstrating its potential clinical translatability.
However, there are significant obstacles to be overcome
before widespread application to patients is possible. As
mentioned in the original review (2), long-term studies are
needed to better understand the efficacy of these approaches.
For example, Dobner et al. (74) showed that injection of a
polymer can improve cardiac function at early time points,
but at later time points, that effect is lost. In addition, a
suitable human cell source still needs to be identified for
cell-based therapies. Although large-scale regeneration will
likely require an exogenous cell source, to date, many studies
have shown improvements with a biomaterial alone, suggesting
the cells that are currently injected may not provide additional
benefit if the appropriate material scaffold is employed. Lastly,
it is critical to keep clinical translation in mind when designing
new biomaterial therapies. For example, numerous injectable
biomaterials have been developed, yet only a few can truly be
delivered via a catheter-based approach.
Conclusions
Biomaterials for the treatment of MI continues to be a
promising approach. Though interest in LV restraints is
waning, much progress has been made in cardiac patches
and injectable biomaterials, with these therapies recently
entering clinical trials. As these materials move towards
clinical translation, it is becoming increasingly important
that we understand the mechanisms by which these thera-
pies affect cardiac function, LV remodeling, and cardiac
electrophysiology.Reprint requests and correspondence: Dr. Karen L. Christman,
Department of Bioengineering, University of California, San
Diego, 9500 Gilman Drive, MC 0412, La Jolla, California 92093.
E-mail: christman@bioeng.ucsd.edu.
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